Dr. Andrés Cervantes is Professor of Medicine at the University of Valencia. He received his training in Medical Oncology at the University Hospital in Valencia (UHV). After that, he got a research fellowship at the Free University Hospital in Amsterdam, where he obtained his PhD degree with a work on multidrug resistance in the Cellular Pharmacology Lab.

He serves as Head of the Department of Medical Oncology at the University Hospital in Valencia, Spain. He is also director of the Cancer Area at the Institute of Health Research INCLIVA.  His main areas of research and clinical interest are gastrointestinal and gynaecologic malignancies as well as phase I trials and new drug development. He started a new drug development program in 2004, where more than 70 drugs have been studied in first in human trials. These antineoplastic agents were conventional cytotoxics, targeted therapies, monoclonal antibodies and immunotherapies. These trials were done with targeted agents and included pharmacokinetics as well as pharmacodynamic end-points. Most of these trials required molecular selection and sequential repetitive biopsies to define the role of specific biomarkers. He is the author of more than three hundred research articles and educational papers published in peer-reviewed journals. He is also one of the Editors in chief of Cancer Treatment Reviews. He is currently the Chair of the Educational Committee of ESMO (European Society for Medical Oncology) and since January 2014, he is also Associate Editor for Gastrointestinal Cancer in Annals of Oncology.

Elected President of ESMO (European Society for Medical Oncology) for 2022-2023.